CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 174 enrolled
Drug / intervention
Latanoprostdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00941525
NCT00941525Phase 4Completed
CompareCT.gov

Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure

Aristotle University Of Thessaloniki·interventional·Posted Jul 17, 2009·Updated Jul 7, 2015

In Brief

A Phase 4 clinical trial evaluating Latanoprost for Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 174 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether 24-hour fluctuation of intraocular pressure (IOP) is associated with central corneal thickness (CCT) in subjects with ocular hypertension or open angle glaucoma and in age-matched controls. Also to evaluate whether mean IOP reduction as a response to latanoprost (0.005% Xalatan) is associated with CCT, after a 4-weeks period of treatment. Also, to evaluate whether 24-hour fluctuation of IOP is associated with corneal hysteresis (CH) measured by Ocular Response Analyzer (ORA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen Angle Glaucoma, Ocular Hypertension
CountriesGreece
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 17, 2009
Enrollment StartSep 1, 2009
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 17.0 years ago

Interventions

Latanoprostdrug

1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period